OCM.191

The Taylor lab Ovarian Cancer Models (OCMs) are patient-derived tumour cell cultures, unfettered by contaminating, genetically normal stromal cells and the microenvironment. OCMs display the hallmark characteristics of HGSOC and retain the unique molecular features of the original tumour. OCMs have extensive proliferative potential, enabling high-resolution cell biology and drug-sensitivity profiling on tumour cells ‘close […]

Contributors

Inventor Institute
Louisa Nelson and Stephen S. Taylor University of Manchester
Cat. #: 161893
Cancer types: Gynaecologic cancer
Research Fields: Cancer
Organism: Human
Tissue: Ovary. NOTE: The precursor of a substantial proportion of HGSOC is likely to be serous tubal intraepithelial carcinoma in the fimbriae of the fallopian tubes
Gender: Female
Morphology: Epithelial
Growth properties: Adherent
Primary citation: Bethany M Barnes et al. 2021. Genome Med. 1,13(1):140. PMID: 34470661
Product description: The Taylor lab Ovarian Cancer Models (OCMs) are patient-derived tumour cell cultures, unfettered by contaminating, genetically normal stromal cells and the microenvironment. OCMs display the hallmark characteristics of HGSOC and retain the unique molecular features of the original tumour. OCMs have extensive proliferative potential, enabling high-resolution cell biology and drug-sensitivity profiling on tumour cells ‘close to the patient’, i.e. without extensive culture and genetic drift. OCMs are clinically annotated, and have been extensively characterised with associated data sets being publicly available (including multi-omics data e.g. exome and RNA sequencing, and single-cell karyotyping). OCMs can also be used to generate PDX, thus enabling in vivo studies of novel therapies. Collectively, this living biobank represents comprehensive platform for basic research and drug development projects (see PMID: 37592171 for a review)
Gender: Female
CRISPR: No
Production details: To establish cultures, red blood cells were lysed, the remaining cellular fraction harvested by centrifugation, disaggregated if necessary then plated in OCMI media. Serial passaging and selective detachment eliminated white blood cells and yielded separate tumour and stromal fractions.
Model description: FIGO 3A; Ascites; BRCA1 mutation (c.3268C>T; [p.Gln1090Ter]; BRCA2 mutation (c.4725C>G [p.Asp1575Glu]); TP53 mutation (p.R248Q)
Initial handling information: Primaria™ Tissue Culture Flasks
Format: Frozen
Storage conditions: Liquid nitrogen (1/2 T75 ISO)
Shipping conditions: Dry ice
Growth medium: OCMI (PMID: 26080861; 32054838) + 5% hyclone FBS
Subculture routine: Split sub-confluent cultures (~90%) 1:2 using 0.25% trypsin. Limit trypsin incubation to 3 mins max, multiple applications of trypsin may be required to remove all the cells from the flask. Trypsin should be neutralised using DMEM containing 20% FBS
Temperature: 37° C
Atmosphere: 5% CO2 & 5% O2
Storage medium: Bambanker freezing solution
Mycoplasma free: Yes
Biosafety level: 2
References:

Bethany M Barnes et al. 2021. Genome Med. 1,13(1):140. PMID: 34470661

Camilla Coulson-Gilmer et al. 2021. J Exp Clin Cancer Res. 16,40(1):323. PMID: 34656146

Anya Golder et al. 2022. NAR Cancer. 12,4(4):zcac036. PMID: 36381271

Related Tools for Cell lines

Cat. # Tool Name
151425 TR146 Cell Line Key Info View Tool
151480 HEK293A EGFP-LC3 Cell Line Key Info View Tool
151484 2fTGH Cell Line Key Info View Tool
151558 MEF Trex1 KO Cell Line Key Info View Tool
151630 PDVC57B Cell Line Key Info View Tool

Related News

UM-UC-10 Cell Line. Image courtesy of the European Collection of Authenticated Cell Cultures (ECACC), UK.
Cell Lines

Popular cell lines now available only from CancerTools.org

Read More
Cell Lines

New cell lines: murine melanocyte and melanoblast cell lines from Dr. Elena Sviderskaya

Read More
Image Reference: 2x PTEN -/- mouse prostate cancer cell lines (MuCap system). Histology staining of syngraft tumours (Van Duijn et al., 2018).
Cell Lines

38 new prostate cancer cell lines

Read More

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.